Zyvox Comparison To Synercid In VRE Infections Recommended By FDA Cmte.
Executive Summary
Pharmacia & Upjohn should conduct clinical trials comparing its oxazolidinone antibiotic Zyvox to Aventis' Synercid in the treatment of infections due to vancomycin-resistant enterococci, FDA's Anti-Infective Drugs Advisory Committee said March 24.
You may also be interested in...
Pathogen-Resistant Antibiotic Indications Questioned By FDA Cmte.
Members of FDA's Anti-Infective Drugs Advisory Committee questioned the usefulness of approving antibiotics specifically for pathogen-resistant indications at a March 24 meeting held to discuss the safety and efficacy of Pharmacia & Upjohn's oxazolidinone antibiotic Zyvox (linezolid)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011